University Hospitals Birmingham NHS Foundation Trust

Running trials

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma

  NCT07356973· Phase 2· CRISM Therapeutics LTD· Source

• Recruiting

  HCMR Re-Imaging Study

  NCT07054073· Christopher Kramer· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

  NCT07443956· NHS Greater Glasgow and Clyde· Source

• Not yet recruiting

  Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension

  NCT07294794· University of Birmingham· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

  NCT07284121· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Active, not recruiting

  Shortened High-dose Palliative Radiotherapy for Lung Cancer

  NCT06483308· University Hospitals Coventry and Warwickshire NHS Trust· Source

• Active, not recruiting

  A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

  NCT06713135· Phase 4· Santhera Pharmaceuticals· Source

• Not yet recruiting

  High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma

  NCT06480396· Phase 3· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source

• Active, not recruiting

  Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

  NCT06230354· Phase 2· Imperial College London· Source

• Recruiting

  Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

  NCT06355583· Phase 2· Imperial College London· Source

• Active, not recruiting

  Intensive Weight Loss Intervention Versus Usual Care for Adults With Severe and Complex Obesity

  NCT06321458· Carsten Dirksen· Source

• Recruiting

  A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

  NCT06045910· Phase 1/2· Cancer Research UK· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source

• Recruiting

  A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

  NCT05789758· Biogen· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

  NCT06063967· Phase 3· AbbVie· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  NCT05848765· Phase 2· University of Birmingham· Source

• Active, not recruiting

  Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

  NCT05696717· Phase 3· Theravance Biopharma· Source

• Recruiting

  European Aortic Data Collection Project

  NCT05896397· Cook Research Incorporated· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Genmab· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

  NCT05325593· Phase 3· Fundación Pública Andaluza para la gestión de la Investigación en Sevilla· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Recruiting

  UK Heart Failure With Preserved Ejection Fraction

  NCT05441839· Manchester University NHS Foundation Trust· Source

• Active, not recruiting

  Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

  NCT05371093· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

  NCT05409066· Phase 3· Genmab· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  Adult SMA Research and Clinical Hub

  NCT06978985· Newcastle-upon-Tyne Hospitals NHS Trust· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

  NCT05186974· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )

  NCT05221229· University Hospital Birmingham· Source

• Active, not recruiting

  COVID-19 Antibody Responses In Cystic Fibrosis

  NCT04863573· Queen's University, Belfast· Source

• Active, not recruiting

  A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

  NCT04554914· Phase 2· Pierre Fabre Medicament· Source

• Recruiting

  Tumour Characterisation to Guide Experimental Targeted Therapy - National

  NCT04723316· The Christie NHS Foundation Trust· Source

• Recruiting

  Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

  NCT04965298· Phase 3· Norfolk and Norwich University Hospitals NHS Foundation Trust· Source

Showing 50 of 76.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Lung cancer4 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Follicular lymphoma2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Multiple myeloma2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Sarcoma2 recruiting
• Spinal muscular atrophy2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic aneurysm1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Kors van der Ent· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

  NCT06068842· AbbVie· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Escient Pharmaceuticals, Inc· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  Big Data for Quality of Life in Head and Neck Cancer

  NCT05315570· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Pfizer· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Eisai Inc.· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

  NCT04524442· Phase 4· Advanced Accelerator Applications· Source

• Completed

  Multi-Centre Study on the Performance of the Ponto BHX Implant System (in Adult Patients)

  NCT04310202· Oticon Medical· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· AbbVie· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  NCT04295577· Royal Marsden NHS Foundation Trust· Source

• Completed

  Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

  NCT03644303· Royal Marsden NHS Foundation Trust· Source

• Completed

  Long Term Extension Trial of Setmelanotide

  NCT03651765· Phase 2/3· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Terminated

  A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT03215030· Phase 1/2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

  NCT02942290· Phase 1· AbbVie· Source

• Completed

  Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

  NCT02733159· Phase 2· University of Birmingham· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· AbbVie· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bronchiectasis9 works · 0 trials
• Sjögren's disease7 works · 0 trials
• Male hypogonadism5 works · 0 trials
• Primary biliary cholangitis5 works · 1 trial
• Cushing's syndrome5 works · 0 trials
• Epidermolysis bullosa5 works · 0 trials
• Pituitary tumours4 works · 0 trials
• Fabry disease4 works · 1 trial
• Antiphospholipid syndrome3 works · 0 trials
• Haemophagocytic lymphohistiocytosis3 works · 0 trials